Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 70, Issue 4 , Pages 361-372 , April 2004

Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function

,Accepted 18 December 2003.

References 

  1. Innis SM. Essential fatty acids in growth and development. Prog. Lipid Res. 1991;30:39–103
  2. Lauritzen L, Hansen HS, Jorgensen MH, Michaelsen KF. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog. Lipid Res. 2001;40:1–94
  3. Hamano H, Nabekura J, Nishikawa M, Ogawa T. Docosahexaenoic acid reduces GABA response in substantia nigra neuron of rat. J. Neurophysiol. 1996;75:1264–1270
  4. Scott BL, Bazan NG. Membrane docosahexaenoate is supplied to the developing brain and retina by the liver. Proc. Natl. Acad. Sci. USA. 1989;86:2903–2907
  5. Innis SM, Dyer RA. Brain astrocyte synthesis of docosahexaenoic acid from n-3 fatty acids is limited at the elongation of docosapentaenoic acid. J. Lipid Res. 2002;43:1529–1536
  6. Moore SA. Local synthesis and targeting of essential fatty acids at the cellular interface between blood and brain (a role for cerebral endothelium and astrocytes in the accretion of CNS docosahexaenoic acid). World Rev. Nutr. Diet. 1994;75:128–133
  7. Moore SA, Yoder E, Murphy S, Dutton GR, Spector AA. Astrocytes, not neurons, produce docosahexaenoic acid (22:6 omega-3) and arachidonic acid (20:4 omega-6). J. Neurochem. 1991;56:518–524
  8. Williard DE, Harmon SD, Kaduce TL, Preuss M, Moore SA, Robbins MEC, et al. Docosahexaenoic acid synthesis from n-3 polyunsaturated fatty acids in differentiated rat brain astrocytes. J. Lipid Res. 2001;42:1368–1376
  9. Rapoport SI, Chang MCJ, Spector AA. Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J. Lipid Res. 2001;42:678–685
  10. Farooqui AA, Horrocks LA, Farooqui T. Deacylation and reacylation of neural membrane glycerophospholipids. J. Mol. Neurosci. 2000;14:123–135
  11. Farooqui AA, Horrocks LA. Plasmalogens, phospholipase A2, and docosahexaenoic acid turnover in brain tissue. J. Mol. Neurosci. 2001;16:263–272
  12. Farooqui AA, Yang H-C, Horrocks LA. Plasmalogens, phospholipases A2, and signal transduction. Brain Res. Rev. 1995;21:152–161
  13. Shikano M, Masuzawa Y, Yazawa K, Takayama K, Kudo I, Inoue K. Complete discrimination of docosahexaenoate from arachidonate by 85kDa cytosolic phospholipase A2 during the hydrolysis of diacyl- and alkenylacylglycerophosphoethanolamine. Biochim. Biophys. Acta Lipids Lipid Metab. 1994;1212:211–216
  14. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells—Autacoids in anti-inflammation. J. Biol. Chem. 2003;278:14677–14687
  15. Bang HO, Dyerberg J, Hjorne N. The composition of food consumed by Greenland eskimos. Acta Med. Scand. 1976;200:69–73
  16. Bougnoux P. n-3 Polyunsaturated fatty acids and cancer. Curr. Opin. Clin. Nutr. Metab. Care. 1999;2:121–126
  17. Terry PD, Rohan TE, Wolk L. Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers (a review of the epidemiologic evidence). Am. J. Clin. Nutr. 2003;77:532–543
  18. Horrocks LA, Yeo YK. Health benefits of docosahexaenoic acid (DHA). Pharmacol. Res. 1999;40:211–225
  19. Neuringer M, Anderson GJ, Connor WE. The essentiality of n-3 fatty acids for the development and function of the retina and brain. Annu. Rev. Nutr. 1988;8:517–541
  20. Neuringer M, Connor WE. N-3 fatty acids in the brain and retina (evidence for their essentiality). Nutr. Rev. 1986;44:285–294
  21. Anderson RE, Landis DJ, Dudley PA. Essential fatty acid deficiency and renewal of rod outer segments in the albino rat. Invest. Ophthalmol. 1976;15:232–236
  22. Connor WE, Neuringer M, Lin DS. Dietary effects on brain fatty acid composition (the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys). J. Lipid Res. 1990;31:237–247
  23. Fernstrom JD. Effects of dietary polyunsaturated fatty acids on neuronal function. Lipids. 1999;34:161–169
  24. Yehuda S, Rabinovitz S, Carasso RL, Mostofsky DI. The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol. Aging. 2002;23:843–853
  25. Hashimoto M, Shinozuka K, Gamoh S, Tanabe Y, Hossain MS, Kwon YM, et al. The hypotensive effect of docosahexaenoic acid is associated with the enhanced release of ATP from the caudal artery of aged rats. J. Nutr. 1999;129:70–76
  26. Barcelo-Coblijn G, Kitajka K, Puskas LG, Hogyes E, Zvara A, Hackler L, et al. Gene expression and molecular composition of phospholipids in rat brain in relation to dietary n-6 to n-3 fatty acid ratio. Biochim. Biophys. Acta. 2003;1632:72–79
  27. Farkas T, Kitajka K, Fodor E, Csengeri I, Lahdes E, Yeo YK, et al. Docosahexaenoic acid-containing phospholipid molecular species in brains of vertebrates. Proc. Natl. Acad. Sci. USA. 2000;97:6362–6366
  28. Kitajka K, Puskas LG, Zvara A, Hackler LJ, Barcelo-Coblijn G, Yeo YK, et al. The role of n-3 polyunsaturated fatty acids in brain (modulation of rat brain gene expression by dietary n-3 fatty acids). Proc. Natl. Acad. Sci. USA. 2002;99:2619–2624
  29. Puskas LG, Kitajka K, Nyakas C, Barcelo-Coblijn G, Farkas T. Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus. Proc. Natl. Acad. Sci. USA. 2003;100:1580–1585
  30. Alexander-North LS, North JA, Kiminyo KP, Buettner GR, Spector AA. Polyunsaturated fatty acids increase lipid radical formation induced by oxidant stress in endothelial cells. J. Lipid Res. 1994;35:1773–1785
  31. Green P, Glozman S, Yavin E. Ethyl docosahexaenoate-associated decrease in fetal brain lipid peroxide production is mediated by activation of prostanoid and nitric oxide pathways. Biochim. Biophys. Acta. Mol. Cell. Biol. Lipids. 2001;1531:156–164
  32. Chalon S, Delion-Vancassel S, Belzung C, Guilloteau D, Leguisquet AM, Besnard JC, et al. Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J. Nutr. 1998;128:2512–2519
  33. Delion S, Chalon S, Guilloteau D, Lejeune B, Besnard JC, Durand G. Age-related changes in phospholipid fatty acid composition and monoaminergic neurotransmission in the hippocampus of rats fed a balanced or an n-3 polyunsaturated fatty acid-deficient diet. J. Lipid Res. 1997;38:680–689
  34. Zimmer L, Delpal S, Guilloteau D, Aioun J, Durand G, Chalon S. Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neurosci. Lett. 2000;284:25–28
  35. Zimmer L, Delion-Vancassel S, Durand G, Guilloteau D, Bodard S, Besnard JC, et al. Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids. J. Lipid Res. 2000;41:32–40
  36. Chalon S, Vancassel S, Zimmer L, Guilloteau D, Durand G. Polyunsaturated fatty acids and cerebral function (focus on monoaminergic neurotransmission). Lipids. 2001;36:937–944
  37. Zimmer L, Vancassel S, Cantagrel S, Breton P, Delamanche S, Guilloteau D, et al. The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids. Am. J. Clin. Nutr. 2002;75:662–667
  38. Minami M, Kimura S, Endo T, Hamaue N, Hirafuji M, Togashi H, et al. Dietary docosahexaenoic acid increases cerebral acetylcholine levels and improves passive avoidance performance in stroke-prone spontaneously hypertensive rats. Pharmacol. Biochem. Behav. 1997;58:1123–1129
  39. Aid S, Vancassel S, Poumes-Ballihaut C, Chalon S, Guesnet P, Lavialle M. Effect of a diet-induced n-3 PUFA depletion on cholinergic parameters in the rat hippocampus. J. Lipid Res. 2003;44:1545–1551
  40. Hogyes E, Nyakas C, Kiliaan A, Farkas T, Penke B, Luiten PG. Neuroprotective effect of developmental docosahexaenoic acid supplement against excitotoxic brain damage in infant rats. Neuroscience. 2003;119:999–1012
  41. Vreugdenhil M, Bruehl C, Voskuyl RA, Kang JX, Leaf A, Wadman WJ. Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. Proc. Natl. Acad. Sci. USA. 1996;93:12559–12563
  42. Gerbi A, Zérouga M, Maixent JM, Debray M, Durand G, Bourre JM. Diet deficient in alpha-linolenic acid alters fatty acid composition and enzymatic properties of Na+, K+-ATPase isoenzymes of brain membranes in the adult rat. J. Nutr. Biochem. 1999;10:230–236
  43. Gerbi A, Debray M, Maixent JM, Chanez C, Bourre JM. Heterogeneous Na+ sensitivity of Na+,K+-ATPase isoenzymes in whole brain membranes. J. Neurochem. 1993;60:246–252
  44. Gerbi A, Zérouga M, Debray M, Durand G, Chanez C, Bourre JM. Effect of fish oil diet on fatty acid composition of phospholipids of brain membranes and on kinetic properties of Na+,K+-ATPase isoenzymes of weaned and adult rats. J. Neurochem. 1994;62:1560–1569
  45. Tsutsumi T, Yamauchi E, Suzuki E, Watanabe S, Kobayashi T, Okuyama H. Effect of a high α-linolenate and high linoleate diet on membrane-associated enzyme activities in rat brain–modulation of Na+, K+- ATPase activity at suboptimal concentrations of ATP. Biol. Pharm. Bull. 1995;18:664–670
  46. Obermeier H, Hrboticky N, Sellmayer A. Differential effects of polyunsaturated fatty acids on cell growth and differentiation of premonocytic U937 cells. Biochim. Biophys. Acta. 1995;1266:179–185
  47. Peters-Golden M, Song K, Marshall T, Brook T. Translocation of cytosolic phospholipase A2 to the nuclear envelope elicits topographically localized phospholipid hydrolysis. Biochem. J. 1996;318:797–803
  48. Slater SJ, Kelly MB, Yeager MD, Larkin J, Ho C, Stubbs CD. Polyunsaturation in cell membranes and lipid bilayers and its effects on membrane proteins. Lipids. 1996;31(Suppl):S189–S192
  49. Garcia MC, Ward G, Ma YC, Salem N, Kim HY. Effect of docosahexaenoic acid on the synthesis of phosphatidylserine in rat brain in microsomes and C6 glioma cells. J. Neurochem. 1998;70:24–30
  50. Salem N, Shingu T, Kim H-Y, Hullin F, Bougnoux P, Karanian JW. Aberrations in membrane structures and function. In:  Karnovsky ML,  Bolis L,  Leaf A editor. Biological Membranes. New York: Alan R. Liss; 1988;p. 319–333
  51. Nishikawa M, Kimura S, Akaike N. Facilitatory effect of docosahexaenoic acid on N-methyl-D-aspartate response in pyramidal neurones of rat cerebral cortex. J. Physiol. (London). 1994;475:83–93
  52. Poling JS, Karanian JW, Salem N, Vicini S. Time- and voltage-dependent block of delayed rectifier potassium channels by docosahexaenoic acid. Mol. Pharmacol. 1995;47:381–390
  53. Xiao YF, Li XY. Polyunsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation. Brain Res. 1999;846:112–121
  54. Young C, Gean PW, Chiou LC, Shen YZ. Docosahexaenoic acid inhibits synaptic transmission and epileptiform activity in the rat hippocampus. Synapse. 2000;37:90–94
  55. Jump DB. Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr. Opin. Lipidol. 2002;13:155–164
  56. Issemann I, Prince RA, Tugwood JD, Green S. The peroxisome proliferator-activated receptor (retinoid x receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs). J. Mol. Endocrinol. 1993;11:37–47
  57. Gottlicher M, Demoz A, Svensson D, Tollet P, Berge RK, Gustafsson JA. Structural and metabolic requirements for activators of the peroxisome proliferator-activated receptor. Biochem. Pharmacol. 1993;46:2177–2184
  58. Ntambi JM, Bene H. Polyunsaturated fatty acid regulation of gene expression. J. Mol. Neurosci. 2001;16:273–278
  59. Cowing BE, Saker KE. Polyunsaturated fatty acids and epidermal growth factor receptor/mitogen-activated protein kinase signaling in mammary cancer. J. Nutr. 2001;131:1125–1128
  60. Calder PC. Dietary fatty acids and the immune system. Nutr. Rev. 1998;56:S70–S83
  61. Wu D, Meydani SN. N-3 polyunsaturated fatty acids and immune function. Proc. Nutr. Soc. 1998;57:503–509
  62. Calder PC, Grimble RF. Polyunsaturated fatty acids, inflammation and immunity. Eur. J. Clin. Nutr. 2002;56:S14–S19
  63. Corey EJ, Shih C, Cashman JR. Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc. Natl. Acad. Sci. USA. 1983;80:3581–3584
  64. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am. J. Clin. Nutr. 2000;71:343S–348S
  65. Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 2003;278:43807–43817
  66. Song C. Effects of n-3 fatty acids on depressive symptoms induced by proinflammatory cytokines in animals. In:  Peet M,  Glen L,  Horrobin DF editor. Phospholipid Spectrum Disorders in Psychiatry and Neurology. Carnforth, Lancashire: Marius Press; 2003;p. 415–422
  67. Chen C, Tonegawa S. Molecular genetic analysis of synaptic plasticity, activity-dependent neural development, learning, and memory in the mammalian brain. Annu. Rev. Neurosci. 1997;20:157–184
  68. Lynch MA, Voss KL. Membrane arachidonic acid concentration correlates with age and induction of long-term potentiation in the dentate gyrus in the rat. Eur. J. Neurosci. 1994;6:1008–1014
  69. McGahon B, Clements MP, Lynch MA. The ability of aged rats to sustain long-term potentiation is restored when the age-related decrease in membrane arachidonic acid concentration is reversed. Neuroscience. 1997;81:9–16
  70. McGahon BM, Martin DSD, Horrobin DF, Lynch MA. Age-related changes in synaptic function (analysis of the effect of dietary supplementation with omega-3 fatty acids). Neuroscience. 1999;94:305–314
  71. Fujita S, Ikegaya Y, Nishikawa M, Nishiyama N, Matsuki N. Docosahexaenoic acid improves long-term potentiation attenuated by phospholipase A2 inhibitor in rat hippocampal slices. Brit. J. Pharmacol. 2001;132:1417–1422
  72. Fujimoto K, Yao K, Miyazaki T, Hirano H, Nishikawa M, Kimura S, et al. The effect of dietary docosahexaenoate on the learning ability of rats. In:  Chandra RK editors. Health Effects of Fish and Fish Oils. ARTS Biomedical: The Netherlands; 1989;p. 275–284
  73. Yamamoto N, Saitoh M, Moriuchi A, Nomura M, Okuyama H. Effect of dietary alpha-linolenic/linoleate balance on brain lipid compositions and learning ability of rats. J. Lipid Res. 1987;28:144–151
  74. Young C, Gean PW, Wu SP, Lin CH, Shen YZ. Cancellation of low-frequency stimulation-induced long-term depression by docosahexaenoic acid in the rat hippocampus. Neurosci. Lett. 1998;247:198–200
  75. Zucker RS. Short-term synaptic plasticity. Annu. Rev. Neurosci. 1989;12:13–31
  76. Itokazu N, Ikegaya Y, Nishikawa M, Matsuki N. Bidirectional actions of docosahexaenoic acid on hippocampal neurotransmissions in vivo. Brain Res. 2000;862:211–216
  77. Honore E, Barhanin J, Attali B, Lesage F, Lazdunski M. External blockade of the major cardiac delayed-rectifier K+ channel (Kv1.5) by polyunsaturated fatty acids. Proc. Natl. Acad. Sci. USA. 1994;91:1937–1941
  78. Aniksztejn L, Ben Ari Y. Novel form of long-term potentiation produced by a K+ channel blocker in the hippocampus. Nature. 1991;349:67–69
  79. Favrelière S, Barrier L, Durand G, Chalon S, Tallineau C. Chronic dietary n-3 polyunsaturated fatty acids deficiency affects the fatty acid composition of plasmenylethanolamine and phosphatidylethanolamine differently in rat frontal cortex, striatum, and cerebellum. Lipids. 1998;33:401–407
  80. Favrelière S, Perault MC, Huguet F, De Javel D, Bertrand N, Piriou A, et al. DHA-enriched phospholipid diets modulate age-related alterations in rat hippocampus. Neurobiol. Aging. 2003;24:233–243
  81. Jones CR, Arai T, Rapoport SI. Evidence for the involvement of docosahexaenoic acid in cholinergic stimulated signal transduction at the synapse. Neurochem. Res. 1997;22:663–670
  82. Barcelo-Coblijn G, Hogyes E, Kitajka K, Puskas LG, Zvara A, Hackler L, et al. Modification by docosahexaenoic acid of age-induced alterations in gene expression and molecular composition of rat brain phospholipids. Proc. Natl. Acad. Sci. USA. 2003;100:11321–11326
  83. Gamoh S, Hashimoto M, Hossain S, Masumura S. Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task in aged rats. Clin. Exp. Pharmacol. Physiol. 2001;28:266–270
  84. N. Kotchabhakdi, R. Tipyasang, W. Thangnipon, N. Jutapukdeekun, C. Jindaduangratn, Effects of different dosages of docosahexaenoic acid (DHA) intake on maze-learning ability and densities of dendritic spines in rats, Soc. Neurosci. Abstracts (2003) Program No. 941.17.
  85. Söderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids. 1991;26:421–425
  86. Guan Z, Wang Y, Cairns NJ, Lantos PL, Dallner G, Sindelar PJ. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J. Neuropathol. Exp. Neurol. 1999;58:740–747
  87. Han XL, Holtzman DM, McKeel DW. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models (molecular characterization using electrospray ionization mass spectrometry). J. Neurochem. 2001;77:1168–1180
  88. Pettegrew JW, Panchalingam K, Hamilton RL, McClure RJ. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 2001;26:771–782
  89. Wells K, Farooqui AA, Liss L, Horrocks LA. Neural membrane phospholipids in Alzheimer disease. Neurochem. Res. 1995;20:1329–1333
  90. A.A. Farooqui, W.Y. Ong, L.A. Horrocks, Plasmalogens, docosahexaenoic acid, and neurological disorders, in: F. Roels, M. Baes, S. de Bies (Eds.), Peroxisomal Disorders and Regulation of Genes, Kluwer Academic/Plenum Publishers, London, 2003, pp. 335–354.
  91. Farooqui AA, Rapoport SI, Horrocks LA. Membrane phospholipid alterations in Alzheimer disease (deficiency of ethanolamine plasmalogens). Neurochem. Res. 1997;22:523–527
  92. Pettegrew JW. Molecular insights into Alzheimer disease. Ann. NY Acad. Sci. 1989;568:5–28
  93. Subbarao KV, Richardson JS, Ang LC. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J. Neurochem. 1990;55:342–345
  94. Kalmijn S, Feskens EJM, Launer LJ, Kromhout D. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am. J. Epidemiol. 1997;145:33–41
  95. Friedland RP. Fish consumption and the risk of Alzheimer disease (is it time to make dietary recommendations?). Arch. Neurol. 2003;60:923–924
  96. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 2003;60:940–946
  97. Farkas E, Luiten PGM. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 2001;64:575–611
  98. Kimura S, Saito H, Minami M, Togashi H, Nakamura N, Ueno K, et al. Docosahexaenoic acid attenuated hypertension and vascular dementia in stroke-prone spontaneously hypertensive rats. Neurotoxicol. Teratol. 2002;24:683–693
  99. Tsukada H, Kakiuchi T, Fukumoto D, Nishiyama S, Koga K. Docosahexaenoic acid (DHA) improves the age-related impairment of the coupling mechanism between neuronal activation and functional cerebral blood flow response (a pet study in conscious monkeys). Brain Res. 2000;862:180–186
  100. Hashimoto M, Hossain S, Shimada T, Sugioka K, Yamasaki H, Fujii Y, et al. Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J. Neurochem. 2002;81:1084–1091
  101. G.P. Lim, F. Calon, F. Yang, O. Ubeda, M. Simmons, K. Hsiao Ashe, S.A. Frautschy, G.M. Cole, Diets enriched with polyunsaturated DHA (docosahexaenoic acid) can lower amyloid levels and plaque burden in an Alzheimer's disease mouse model, Soc. Neurosci. Abstracts (2003) Program No. 201.25.
  102. M.C. de Wilde, I. Leenders, L.M. Broersen, A.A.M. Kuipers, E.M. van der Beek, A.J. Kiliaan, The omega-3 fatty acid docosahexaenoic acid (DHA) inhibits the formation of beta amyloid in CHO7PA2 cells, Soc. Neurosci. Abstracts (2003) Program No. 730.11.
  103. Kim HY, Akbar M, Lau A, Edsall L. Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n-3). Role of phosphatidylserine in antiapoptotic effect. J. Biol. Chem. 2000;275:35215–35223
  104. Kishida E, Yano M, Kasahara M, Masuzawa Y. Distinctive inhibitory activity of docosahexaenoic acid against sphingosine-induced apoptosis. Biochim. Biophys. Acta Lipids Lipid Metab. 1998;1391:401–408
  105. Oehler MK, Sütterlin M, Caffier H. CASA and CA 125 in diagnosis and follow-up of advanced ovarian cancer. Anticancer Res. 1999;19:2513–2518
  106. Rotstein NP, Aveldaño MI, Barrantes FJ, Roccamo AM, Politi LE. Apoptosis of retinal photoreceptors during development in vitro (protective effect of docosahexaenoic acid). J. Neurochem. 1997;69:504–513
  107. Rotstein NP, Politi LE, Aveldaño MI. Docosahexaenoic acid promotes differentiation of developing photoreceptors in culture. Invest. Ophthalmol. Vis. Sci. 1998;39:2750–2758
  108. Rotstein NP, Politi LE, German OL, Girotti R. Protective effect of docosahexaenoic acid on oxidative stress-induced apoptosis of retina photoreceptors. Invest. Ophthalmol. Vis. Sci. 2003;44:2252–2259
  109. Akbar M, Kim HY. Protective effects of docosahexaenoic acid in staurosporine-induced apoptosis (involvement of phosphatidylinositol-3 kinase pathway). J. Neurochem. 2002;82:655–665
  110. Siddiqui RA, Wiesehan J, Stillwel W, Jenski L, Kovacs R. Prevention of cytotoxic effects of docosahexaenoic acid in Jurkat leukemic cells by phosphatidic acid. FASEB J. 2001;15:A282
  111. Siddiqui RA, Jenski LJ, Harvey KA, Wiesehan JD, Stillwell W, Zaloga GP. Cell-cycle arrest in Jurkat leukaemic cells (a possible role for docosahexaenoic acid). Biochem. J. 2003;371:621–629
  112. Martı́nez M, Vázquez E, Garcı́a-Silva MT, Manzanares J, Bertran JM, Castelló F, et al. Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders. Am. J. Clin. Nutr. 2000;71:376S–385S
  113. Moser HW. Peroxisomal disorders. Clin. Biochem. 1991;24:343–351
  114. Hibbeln JR, Salem N. Dietary polyunsaturated fatty acids and depression (when cholesterol does not satisfy). Am. J. Clin. Nutr. 1995;62:1–9
  115. Horrobin DF, Bennett CN. Phospholipid metabolism and the pathophysiology of psychiatric and neurological disorders. In:  Peet M,  Glen L,  Horrobin DF editor. Phospholipid Spectrum Disorders in Psychiatry and Neurology. Carnforth, Lancashire: Marius Press; 2003;p. 3–47
  116. Yoshida S, Sato A, Okuyama H. Pathophysiological effects of dietary essential fatty acid balance on neural systems. Jpn. J. Pharmacol. 1998;77:11–22
  117. Burgess JR, Stevens L, Zhang W, Peck L. Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. Am. J. Clin. Nutr. 2000;71:327S–330S
  118. Mahadik SP, Mukherjee S, Horrobin DF, Jenkins K, Correnti EE, Scheffer RE. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients (comparison with bipolar patients and normal subjects). Psychiatry Res. 1996;63:133–142
  119. van West D, Maes M. Fatty acid composition in major depression. In:  Peet M,  Glen L,  Horrobin DF editor. Phospholipid Spectrum Disorders in Psychiatry and Neurology. Carnforth, Lancashire: Marius Press; 2003;p. 423–429
  120. Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol. Scand. 2000;102:143–149
  121. Gamoh S, Hashimoto M, Sugioka K, Hossain MS, Hata N, Misawa Y, et al. Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience. 1999;93:237–241
  122. Okada M, Amamoto T, Tomonaga M, Kawachi A, Yazawa K, Mine K, et al. The chronic administration of docosahexaenoic acid reduces the spatial cognitive deficit following transient forebrain ischemia in rats. Neuroscience. 1996;71:17–25
  123. Billman GE, Hallaq H, Leaf A. Prevention of ischemia-induced ventricular fibrillation by ω−3 fatty acids. Proc. Natl. Acad. Sci. USA. 1994;91:4427–4430
  124. Terano T, Fujishiro S, Ban T, Yamamoto K, Tanaka T, Noguchi Y, et al. Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases. Lipids. 1999;34(Suppl.):S345–S346
  125. Hossain MS, Hashimoto M, Masumura S. Influence of docosahexaenoic acid on cerebral lipid peroxide level in aged rats with and without hypercholesterolemia. Neurosci. Lett. 1998;244:157–160
  126. Hossain MS, Hashimoto M, Gamoh S, Masumura S. Antioxidative effects of docosahexaenoic acid in the cerebrum versus cerebellum and brainstem of aged hypercholesterolemic rats. J. Neurochem. 1999;72:1133–1138
  127. Martı́nez M. Severe deficiency of docosahexaenoic acid in peroxisomal disorders (a defect of delta 4 desaturation?). Neurology. 1990;40:1292–1298
  128. Martı́nez M. Docosahexaenoic acid therapy in docosahexaenoic acid-deficient patients with disorders of peroxisomal biogenesis. Lipids. 1996;31:S145–S152
  129. Infante JP, Huszagh VA. Zellweger syndrome knockout mouse models challenge putative peroxisomal beta-oxidation involvement in docosahexaenoic acid (22: 6n-3) biosynthesis. Mol. Genet. Metab. 2001;72:1–7
  130. Hamazaki T, Sawazaki S, Itomura M, Asaoka E, Nagao Y, Nishimura N, et al. The effect of docosahexaenoic acid on aggression in young adults—a placebo-controlled double-blind study. J. Clin. Invest. 1996;97:1129–1133

PII: S0952-3278(04)00007-9

doi: 10.1016/j.plefa.2003.12.011

Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 70, Issue 4 , Pages 361-372 , April 2004

Article Tools

* Image Usage & Resolution